Loading...

UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Steven Barriere, PharmD

Title(s)Clinical Professor, Clinical Pharmacy
SchoolSchool of Pharmacy
Phone415-476-2352
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPharm.D.1973 Pharmacy

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Niederman MS, Lee PC, Barriere SL, Barnes CN, Castaneda-Ruiz B. Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials. Infect Dis Ther. 2019 Sep; 8(3):445-452. PMID: 31372837.
      View in: PubMed
    2. Smart JI, Corey GR, Stryjewski ME, Wang W, Barriere SL. Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates. Diagn Microbiol Infect Dis. 2017 Mar; 87(3):268-271. PMID: 28038840.
      View in: PubMed
    3. Smart JI, Corey GR, Stryjewski ME, Wang W, Barriere SL. Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates. Infect Dis Ther. 2016 Dec; 5(4):535-544. PMID: 27718118.
      View in: PubMed
    4. Lacy MK, Stryjewski ME, Wang W, Hardin TC, Nogid B, Luke DR, Shorr AF, Corey GR, Barriere SL. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality. Clin Infect Dis. 2015 Sep 15; 61 Suppl 2:S87-93. PMID: 26316562.
      View in: PubMed
    5. Pushkin R, Barriere SL, Wang W, Corey GR, Stryjewski ME. Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance. Antimicrob Agents Chemother. 2015 Oct; 59(10):6170-4. PMID: 26248356.
      View in: PubMed
    6. Worboys PD, Wong SL, Barriere SL. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur J Clin Pharmacol. 2015 Jun; 71(6):707-714. PMID: 25939708.
      View in: PubMed
    7. Barriere SL. Clinical, economic and societal impact of antibiotic resistance. Expert Opin Pharmacother. 2015 Feb; 16(2):151-3. PMID: 25483564.
      View in: PubMed
    8. Corey GR, Rubinstein E, Stryjewski ME, Bassetti M, Barriere SL. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis. 2015 Mar 01; 60(5):787-96. PMID: 25472944.
      View in: PubMed
    9. McConeghy KW, Liao S, Clark D, Worboys P, Barriere SL, Rodvold KA. Variability in telavancin cross-reactivity among vancomycin immunoassays. Antimicrob Agents Chemother. 2014 Dec; 58(12):7093-7. PMID: 25223996.
      View in: PubMed
    10. Barriere SL, Farrell DJ, Rhomberg PR, Jones RN. Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease. Diagn Microbiol Infect Dis. 2014 Dec; 80(4):327-9. PMID: 25306423.
      View in: PubMed
    11. Stryjewski ME, Lentnek A, O'Riordan W, Pullman J, Tambyah PA, Miró JM, Fowler VG, Barriere SL, Kitt MM, Corey GR. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis. 2014 May 23; 14:289. PMID: 24884578.
      View in: PubMed
    12. Rubinstein E, Stryjewski ME, Barriere SL. Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia. Infect Drug Resist. 2014; 7:129-35. PMID: 24876786.
      View in: PubMed
    13. Barriere SL, Stryjewski ME, Corey GR, Genter FC, Rubinstein E. Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies. BMC Infect Dis. 2014 Apr 04; 14:183. PMID: 24708675.
      View in: PubMed
    14. Barriere SL. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future Microbiol. 2014; 9(3):281-9. PMID: 24450506.
      View in: PubMed
    15. Corey GR, Kollef MH, Shorr AF, Rubinstein E, Stryjewski ME, Hopkins A, Barriere SL. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother. 2014; 58(4):2030-7. PMID: 24419353.
      View in: PubMed
    16. Ero MP, Harvey NR, Harbert JL, Janc JW, Chin KH, Barriere SL. Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers. J Thromb Thrombolysis. 2014; 38(2):235-40. PMID: 24132401.
      View in: PubMed
    17. Stryjewski ME, Barriere SL, Rubinstein E, Genter FC, Lentnek AL, Magana-Aquino M, Luna CM, Niederman MS, Torres A, Corey GR. Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia. Int J Antimicrob Agents. 2013 Oct; 42(4):367-9. PMID: 23891527.
      View in: PubMed
    18. Krause KM, Blais J, Lewis SR, Lunde CS, Barriere SL, Friedland HD, Kitt MM, Benton BM. In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2012 Dec; 74(4):429-31. PMID: 23083812.
      View in: PubMed
    19. Stryjewski ME, Potgieter PD, Li YP, Barriere SL, Churukian A, Kingsley J, Corey GR. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012 Nov; 56(11):5476-83. PMID: 22869571.
      View in: PubMed
    20. Stryjewski ME, Barriere SL, O'Riordan W, Dunbar LM, Hopkins A, Genter FC, Corey GR. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections. J Antimicrob Chemother. 2012 Jun; 67(6):1496-502. PMID: 22416054.
      View in: PubMed
    21. Samara E, Shaw JP, Barriere SL, Wong SL, Worboys P. Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrob Agents Chemother. 2012 Apr; 56(4):2067-73. PMID: 22252798.
      View in: PubMed
    22. Sharma-Kuinkel BK, Ahn SH, Rude TH, Zhang Y, Tong SY, Ruffin F, Genter FC, Braughton KR, Deleo FR, Barriere SL, Fowler VG. Presence of genes encoding panton-valentine leukocidin is not the primary determinant of outcome in patients with hospital-acquired pneumonia due to Staphylococcus aureus. J Clin Microbiol. 2012 Mar; 50(3):848-56. PMID: 22205797.
      View in: PubMed
    23. Nienaber JJ, Sharma Kuinkel BK, Clarke-Pearson M, Lamlertthon S, Park L, Rude TH, Barriere S, Woods CW, Chu VH, Marín M, Bukovski S, Garcia P, Corey GR, Korman T, Doco-Lecompte T, Murdoch DR, Reller LB, Fowler VG. Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins. J Infect Dis. 2011 Sep 01; 204(5):704-13. PMID: 21844296.
      View in: PubMed
    24. Barriere SL, Goldberg MR, Janc JW, Higgins DL, Macy PA, Adcock DM. Effects of telavancin on coagulation test results. Int J Clin Pract. 2011 Jul; 65(7):784-9. PMID: 21564449.
      View in: PubMed
    25. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011 Jan 01; 52(1):31-40. PMID: 21148517.
      View in: PubMed
    26. Barriere SL. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiol. 2010 Dec; 5(12):1765-73. PMID: 21080861.
      View in: PubMed
    27. Krause KM, Barriere SL, Kitt MM, Benton BM. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies. Diagn Microbiol Infect Dis. 2010 Oct; 68(2):181-5. PMID: 20846593.
      View in: PubMed
    28. Barriere SL. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective. Clin Infect Dis. 2010 Aug 01; 51 Suppl 1:S4-9. PMID: 20597670.
      View in: PubMed
    29. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL. Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy. 2010 Aug; 30(8):806-11. PMID: 20653356.
      View in: PubMed
    30. Wong SL, Goldberg MR, Ballow CH, Kitt MM, Barriere SL. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy. 2010 Feb; 30(2):136-43. PMID: 20099988.
      View in: PubMed
    31. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy. 2010 Jan; 30(1):35-42. PMID: 20030471.
      View in: PubMed
    32. Bae IG, Tonthat GT, Stryjewski ME, Rude TH, Reilly LF, Barriere SL, Genter FC, Corey GR, Fowler VG. Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J Clin Microbiol. 2009 Dec; 47(12):3952-7. PMID: 19846653.
      View in: PubMed
    33. Patel JH, Churchwell MD, Seroogy JD, Barriere SL, Grio M, Mueller B. Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study. Int J Artif Organs. 2009 Oct; 32(10):745-51. PMID: 19943236.
      View in: PubMed
    34. Wong SL, Sörgel F, Kinzig M, Goldberg MR, Kitt MM, Barriere SL. Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. J Clin Pharmacol. 2009 Jul; 49(7):816-23. PMID: 19443680.
      View in: PubMed
    35. Wilson SE, O'Riordan W, Hopkins A, Friedland HD, Barriere SL, Kitt MM. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg. 2009 Jun; 197(6):791-6. PMID: 19095213.
      View in: PubMed
    36. Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy. 2008 Dec; 28(12):1471-82. PMID: 19025428.
      View in: PubMed
    37. Wong SL, Barriere SL, Kitt MM, Goldberg MR. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother. 2008 Oct; 62(4):780-3. PMID: 18586659.
      View in: PubMed
    38. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008 Jun 01; 46(11):1683-93. PMID: 18444791.
      View in: PubMed
    39. Lodise TP, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2008 Jul; 52(7):2300-4. PMID: 18426898.
      View in: PubMed
    40. Hatton RC, Chavez ML, Jackson E, Maurey J, Barriere SL, Couchenour R, Evens RP, Gunning K, Hume AL, Hutchison LC, Matzke GR, Noviasky JA, Rospond RM, Kelloway JS, Stevenson JG, Vanderveen RP, Verme-Gibboney CN, Walters D. Pharmacists and industry: guidelines for ethical interactions. Pharmacotherapy. 2008 Mar; 28(3):410-20. PMID: 18294122.
      View in: PubMed
    41. Campbell SJ, Deshmukh HS, Nelson CL, Bae IG, Stryjewski ME, Federspiel JJ, Tonthat GT, Rude TH, Barriere SL, Corey R, Fowler VG. Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J Clin Microbiol. 2008 Feb; 46(2):678-84. PMID: 18077636.
      View in: PubMed
    42. Gotfried MH, Shaw JP, Benton BM, Krause KM, Goldberg MR, Kitt MM, Barriere SL. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008 Jan; 52(1):92-7. PMID: 17923490.
      View in: PubMed
    43. Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, Vallée M, Fowler VG, Morganroth J, Barriere SL, Kitt MM, Corey GR. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006 Mar; 50(3):862-7. PMID: 16495243.
      View in: PubMed
    44. Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, Fowler VG, Chu VH, Spencer E, Barriere SL, Kitt MM, Cabell CH, Corey GR. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005 Jun 01; 40(11):1601-7. PMID: 15889357.
      View in: PubMed
    45. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol. 2004 Jul; 44(7):689-95. PMID: 15199073.
      View in: PubMed
    Steven's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (181) concept(s)
    _
    Similar People
    People who share similar concepts with this person.
    See all (60) people
    _
    Same Department
    Search Department
    ↑